Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Carcinoma, Hepatocellular 2Breast Neoplasms 2Sarcoma 1Prostatic Neoplasms 1Oligodendroglioma 1Neoplasms 1Liver Neoplasms, Experimental 1Liver Neoplasms 1Hemangiosarcoma 1Gliosarcoma 1Glioma 1Glioblastoma 1Carcinoma, Renal Cell 1Brain Neoplasms 1Astrocytoma 1Adenoma, Liver Cell 1

Interventions

Temozolomide 4Erlotinib Hydrochloride 4Bevacizumab 4temsirolimus 3Radiotherapy 3Carboplatin 3etoposide phosphate 2Sirolimus 2Magnetic Resonance Spectroscopy 2Imatinib Mesylate 2Cetuximab 2Carmustine 2veliparib 1transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38) 1terameprocol 1sodium thiosulfate 1romidepsin 1picropodophyllin 1perifosine 1octadecyl-(N,N-dimethylpiperidino-4-yl)-phosphate 1mirdametinib 1irofulven 1efaproxiral 1carotuximab 1cabazitaxel 1acetyl-prolyl-histidyl-seryl-cysteinyl-asparaginamide 1Vorinostat 1Transurethral Resection of Bladder 1Surgical Procedures, Operative 1Spinal Puncture 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Oligodendroglioma × carotuximab × Clear all
NCT01648348 2018-05-23

Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 1/2 Completed
116 enrolled 17 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡